CellRapeutics™ Leukopak from Covid-19 Donor (XS-0426-XU234)

Name: CellRapeutics™ Leukopak from Covid-19 Donor
SKU: XS-0426-XU234
Rating: 5 (1 reviews)

Online Inquiry Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product features a comprehensive leukocyte collection from donors with a documented history of SARS-CoV-2 infection. The cellular matrix contains high frequencies of virus-specific memory B cells and long-lived CD4⁺ and CD8⁺ T cells. It is specifically curated for the study of durable antiviral immunity, the characterization of the "Long COVID" immune landscape, and the development of next-generation neutralizing antibodies or T-cell therapies.

Specific Inquiry

Add to Cart

Donor Information

Product Name
CellRapeutics™ Leukopak from Covid-19 Donor

Cat. No.
XS-0426-XU234

Donor Age
Young Adult, Middle-Aged

Donor Health
Donors have a confirmed history of SARS-CoV-2 infection. The immune population is characterized by persistent viral-specific memory T and B cells and a signature of recovered anti-viral immune homeostasis.

Ethnicity
Diverse backgrounds available.

Anticoagulant
Acid Citrate Dextrose or Heparin, optimized to stabilize SARS-CoV-2 specific memory B/T cells and prevent hypercoagulability-related cell loss.

Additional Donor Information
Each lot features a Leukopak from donors with a documented history of SARS-CoV-2 infection. Profiles include time since recovery, vaccination status, and severity of initial symptoms to support research on long-term immune memory and post-viral sequelae.

Clinical Profile
History of SARS-CoV-2 infection, vaccination status, and severity of clinical symptoms during infection.

Additional Information

Medication History
Available upon request. Documentation of vaccination status, history of antiviral treatments, and time elapsed between clinical resolution and leukapheresis.

Formulation
Cryopreserved or Fresh options available.

Cell Purity
>90%

Cell Viability
>90%

Mycoplasma Testing
Negative

Sterility Testing
Negative

Genetic Stability Testing
The donor cells maintain their native genetic profile, exhibiting no karyotypic abnormalities or chromosomal instabilities typically associated with prolonged ex vivo expansion.

Application
Drug Discovery, Immuno-oncology Research

Research Use Only
RUO

Quality Control
Each product batch is strictly validated for high cellular viability, specific immune cell counts, and pathogen-free safety, ensuring consistent clinical phenotypes and ethical compliance for advanced immunological research.

Storage
Store fresh Leukopaks at 2°C to 8°C for immediate use, cryopreserved samples must be kept in liquid nitrogen vapor phase below -150°C.

Shiping
Dry Ice

Handling Notes
Process fresh cells within 48 hours or perform rapid thawing of cryovials in a 37°C water bath followed by gradual dilution to maximize recovery.

Warnings
Treat as potentially biohazardous human-derived material and handle strictly under BSL-2 guidelines using appropriate personal protective equipment.

Size
Full Bag, Half Bag

Keywords
CellRapeutics™ Leukopak from Covid-19 Donor, Leukopak, Covid-19

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for CellRapeutics™ Leukopak from Covid-19 Donor (XS-0426-XU234). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.